Drugs / DLX105
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01595997 | Feb → Aug 2012 | psoriasis | Delenex Therapeutics AG | Completed | No outcome recorded |
| Phase 1/2 | NCT00819572 | Dec 2008 → Sep 2010 | osteoarthritis | ESBATech AG | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01936337 Comparator | Aug 2013 → Jun 2014 | psoriasis | Delenex Therapeutics AG | Completed | No outcome recorded |
| Phase 2 | NCT01624376 Comparator | Jun 2012 → Feb 2013 | Crohn disease | Delenex Therapeutics AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLX105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01936337 ↗ |
| Modality | Protein / enzyme biologic | “DLX105, a single-chain (scFv) antibody fragment against TNF-alpha” NCT00819572 ↗ |
| Route | Other | “intra-articular injection of DLX105 to the knee joint” NCT00819572 ↗ |
| Target | TNF | “DLX105, a single-chain (scFv) antibody fragment against TNF-alpha” NCT00819572 ↗ |